Investor Relations

View pipeline chart

We have applied our expertise in multivalency to discover product candidates and lead compounds in a number of therapeutic areas.

 

Theravance (NASDAQ: THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The Company's key programs include: RELOVAIRTM, LAMA/LABA (‘719/vilanterol (VI)) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc, and our oral Peripheral Mu Opioid Receptor Antagonist (PµMA) program. By leveraging its proprietary insight of multivalency to drug discovery, Theravance is pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need.

View all »   RSSRecent Releases

Feb 22, 2012
Theravance to Present at the Cowen and Company 32nd Annual Health Care Conference

Feb 9, 2012
Theravance Reports Fourth Quarter and Full Year 2011 Financial Results

View all »Presentations & Events

Feb 28, 2012 at 8:30 AM ET
RBC Capital Markets' Global Healthcare Conference

Feb 29, 2012 at 9:30 AM ET
Citi Global Healthcare Conference

Search
Investor Relations
Form content here please :)